



Hot Topics on Respiratory Vaccines: Clearing the Air on Liability and Practice Considerations

October 21, 2025

5:00 – 6:00 pm ET



Steven Bondi, JD, MD, FAAP *American Academy of Pediatrics*



Brigid Groves, PharmD, MS
American Pharmacists Assoc.



Nivedita Mohanty, MD, MSAmerican Academy of Pediatrics



Paul Rodríguez, JD
Common Health Coalition



Charlene Wong, MD, MSHP
Common Health Coalition



Chelsea Cipriano, MPH Common Health Coalition

Nivedita (Nita) Mohanty

I have no relevant financial relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation



Our time together today

5:00 - 5:05 pm Welcome
Nivedita (Nita) Mohanty, MD, MS, FAAP; American Academy of Pediatrics

5:05 - 5:10 pm Situational Update

Chelsea Cipriano, MPH; Common Health Coalition

Brigid Groves, PharmD, MS; American Pharmacists Association

5:10 - 5:45 pm Shared Clinical Decision-Making, Liability & Informed Consent
Charlene Wong, MD, MPH; Common Health Coalition
Steve Bondi, JD, MD, FAAP; AAP Committee on Medical Liability and
Risk Management
Paul Rodriguez, JD; Common Health Coalition

5:45 - 6:00 pm Q&A

Liability Considerations and Practice

- The information in this webinar does not constitute legal advice. The purpose of this webinar is to share legal principles.
- Our focus today is on Respiratory Virus Season and most significantly around considerations for COVID-19





Situational Update



Chelsea Cipriano

I have no relevant financial relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation



2025-2026 Combined Respiratory **Vaccine Recommendations**

Influenza Vaccine

RSV Immunization

COVID-19 Vaccine

All children 6-23 months +

children 2-18 years with

risk factors or if parent

desires vaccine AAP, AAFP

Infants and Children

All children 6 months and older

All

At any point in pregnancy

Some children 6 months to 8 years may need multiple doses All infants < 8 months + children 8-19 months with risk factors

(nirsevimab, clesrovimab), typically Oct-Mar, if no maternal RSV vaccine

32-36 weeks gestation

(Pfizer, Abrysvo only) Typically Sept-Jan

ACOG, AAFP, CDC

All

At any point in pregnancy

ACOG, AAFP

Adults

18-50

Pregnancy

All

AAFP, CDC

ACOG, AAFP, CDC

See Pregnancy

AAFP, CDC

All

Especially important for people with risk factors or who have never received a vaccine AAFP, IDSA

Especially important for people with risk factors or who have never received a vaccine AAFP, IDSA

All

Adults 50+

All

High-dose, recombinant or adjuvanted flu vaccine preferred for 65+, if available AAFP, CDC

All 75+ and adults 50-74 with risk factors

One lifetime dose of RSV vaccine



Last updated 10/20/25

Recommendations **Table**





On September 19, 2025, ACIP recommended that vaccination for COVID-19 be determined by individuals – in consultation with a health care provider – for everyone aged 6 months and older.

ACIP explicitly voted **against** requiring prescriptions.



COVID-19 Vaccine Availability for Adults, by State



NH

State Action

map



"4 Facts on COVID-19 Vaccines This Fall"



High Risk list



MOST AMERICANS ARE CONSIDERED "HIGH RISK"

More than 75% of Americans have a condition that qualifies them as "high risk."

Risk factors for severe COVID-19 illness:

Adults over the age of 65 Children with certain conditions

Underlying medical conditions

Living or working in high risk setting

Other conditions that increase risk:

- Cancer
- · Cerebrovascular disease
- · Chronic kidney disease
- Chronic liver disease
- Chronic lung disease
- Cystic fibrosis
- Dementia or other neurological conditions
- Diabetes (type 1 or type 2)
- Disabilities
- Heart conditions
- · Hemoglobin blood disorders
- HIV infection

- Immunocompromised condition or weakened immune system
- Mental health conditions
- · Overweight and obesity
- · Physical inactivity
- Pregnancy
- Smoking current or former
- Solid organ or blood stem cell transplants
- · Substance use disorders
- Tuberculosis



Brigid Groves

I have disclosed a consulting relationship with Pfizer for an educational speaking engagement that did not involve Pfizer commercial products.


I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation.



Pharmacists' Authority to Vaccinate Against COVID-19 by Age

As of August 2024







Shared Clinical Decision-Making, Liability & Informed Consent



Charlene Wong

I have disclosed a past advisory relationship with Sanofi for future adolescent vaccines.

I have no relevant financial relationships with the manufacturer(s) of commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation.

Shared Clinical Decision-Making

- What? Clinicians talk with a patient about the benefits and risks of vaccination for them. This type of counseling already occurs often.
- Who? Primary care physicians, specialist physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists can practice shared clinical decision making in all 50 states

See Common Health Coalition's SCDM Guide





Shared Clinical Decision-Making



Can be conducted in many ways - and you're probably already doing it!

I recommend you (your child) get the updated COVID-19 vaccine today. The vaccine information sheets you have explain the vaccine's benefits and potential risks.

Do you have any questions about the vaccines that you want to talk about?

Sample EHR Documentation (e.g., dot phrase):

The patient/caregiver & I engaged in shared clinical decision-making about the benefits and risks of the 2025-2026 COVID-19 vaccine. This discussion included an opportunity for them to ask questions. No contraindication to vaccination was identified, & the patient/caregiver and I collaboratively determined the patient would benefit from vaccination. A COVID-19 vaccine was ordered in the context of shared clinical decision making & educational materials were provided.

Where applicable for patients with underlying conditions add: The patient has (indicate underlying condition).



Shared Clinical Decision-Making



Can be conducted in many ways - and you're probably already doing it! For example:

Now is when I recommend the updated COVID-19 and flu vaccines for you (your child).

I'm worried about what if my son has a bad reaction

I understand that you're worried about COVID-19 vaccine side effects, and that's perfectly normal. Most people have minor side effects - like a sore or red arm - or no side effects. What's your main concern?

I heard there is a risk of heart problems

Heart inflammation after a COVID-19 vaccine is rare, especially in your son's age group. The risk of this kind of heart inflammation is much higher after getting COVID-19 infection than after vaccination itself.



Paul Rodriguez

I have no relevant financial relationships with the manufacturer(s) of commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation.

Steven Bondi

I have no relevant financial relationships with the manufacturer(s) of commercial product(s) and/or provider(s) of commercial services discussed in this activity.

I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation.

Clinician Liability

Standard negligence framework:



- Standard of care informed by:
 - Evidence & Published studies
 - Reflected in:
 - FDA labeling
 - ACIP recommendations
 - Professional society guidance
- Determined by "trier of fact" = judge or jury

Clinician Liability: Federal Vaccine Protections

Vaccine Injury Compensation Program (VICP)

National Childhood Vaccine Injury Act of 1986

- No-fault compensation for covered vaccines
- Paid through trust fund
- Providers not initially involved
- Patients must exhaust process before suing a provider
- Coverage depends on published Vaccine Injury Table
 - o Routine childhood, including Flu
 - Not COVID-19 and RSV

Countermeasures Injury Compensation Program (CICP)

Public Readiness and Emergency Preparedness (PREP) Act of 2005

- No-fault compensation for covered vaccines
- Paid through separate trust fund
- Providers not involved
- Coverage depends on PREP Act
 - Includes COVID-19
 - o For pharmacists (+ interns and techs):
 - ACIP rec vaccines (ages 3-18)
 - Seasonal influenza vaccines (ages 19+)
 - COVID-19 vaccines (ages 3+)

Clinician Liability: Practical Legal Implications

- FDA label change ≠ withdrawal of ACIP recommendation
 - Off-Label use:
 - Common, legally permissible if aligned with standard of care
 - If no PREP Act protection → standard rules still apply, like RSV/travel vaccines
- Shift from "routine use" to "Shared Clinical Decision-Making" for COVID
 - Reflects <u>individualized risk-benefit assessment</u>, not withdrawal of support
 - Heightened emphasis on documenting individualized assessment
 - ACIP recommendation remains in place → no coverage change under ACA



Informed Consent (and Informed Refusal)

Overview:

- Risks
- Benefits
- Alternatives

Important to note:

- Generally uses negligence standard for adequacy
- Generally uses a "reasonable person" standard in absence





Q&A

CHC Resources

- Toolkits
- Regulatory/legal briefs
- Scenario planning tools
- Explainers
- Recommendations
- FAQs



AAP Resources

COVID-19 Vaccine FAQs



Pediatric COVID-19 Vaccine Dosing Guide



Share your liability-related concerns/administration issues here

